
RealRate

PHARMACEUTICAL 2023

Viatris Inc Rank 218 of 446









PHARMACEUTICAL 2023

Viatris Inc Rank 218 of 446



The relative strengths and weaknesses of Viatris Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viatris Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 149% points. The greatest weakness of Viatris Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 53% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,635,400
Cost of Goods Sold	9,765,700
Intangible Assets	33,032,900
Liabilities, Current	6,746,200
Liabilities, Non-Current	19,771,700
Other Assets	3,329,400
Other Compr. Net Income	-1,016,900
Other Expenses	1,367,800
Other Liabilities	2,432,000
Other Net Income	1,790,700
Other Revenues	16,262,700
Property and Equipment	3,024,500
Research and Development	662,200
Selling, General and Administrative Expense	4,179,100

Output Variable	Value in 1000 USD
Assets	50,022,200
Liabilities	28,949,900
Expenses	15,974,800
Revenues	16,262,700
Stockholders Equity	21,072,300
Net Income	2,078,600
Comprehensive Net Income	1,570,150
Economic Capital Ratio	96%

